Scientific Publications

• October, 2024

  Haque EU, Jabbour E, Senapati J, Haddad FG. Olverembatinib for the treatment of chronic myeloid leukemia in chronic phase. Ann Blood . 2024;9: 27.

  View
• October, 2024

  Fan S, Wang L, Lu Y, Li Z. Olverembatinib combined with blinatumomab in treating T315I-mutated Philadelphia chromosome-positive acute lymphoblastic leukemia: two-case report. Ann Hematol . 2024;103: 525-532.

  View
• October, 2024

  Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H. Olverembatinib (HQP1351) overcomes ponatinib and/or asciminib resistance in patients with heavily pretreated/refractory chronic myeloid leukemia (CML). Oral presentation presented at: 2024 ESH John Goldman Conference on Chronic Myeloid Leukemia; September 27-29, 2024; Prague, Czech Republic. .

  View
• October, 2024

  Jabbour E, Oehler VG, Koller PB, Jamy O, Lomaia E, Hunter AM, Uspenskaya O, Samarina S, Mukherjee S, Cortes JE, Baer MR, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Jiang L, Wang C, Wang H, Yang D, Zhai Y, Kantarjian H . Olverembatinib (HQP1351) overcomes ponatinib and/or asciminib resistance in patients with heavily pretreated/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Clin Lymphoma Myeloma Leuk . 2024;24(suppl 1): S371. [Poster presented at: SOHO 2024 Annual Meeting; September 4-7, 2024; Houston, TX].

  View
• October, 2024

  Qiu H, Yang C, Zhou Z, Zhou Y, Wan X, Li N, Tao K, Li Y, Wu X, Chen Z, Men L, Xiong Y, Liang E, Wang C, Yang D, Zhai Y, Xu R . 1722MO: Updated efficacy results of olverembatinib (HQP1351) in patients with succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and potential mechanisms of action (MOA). Ann Oncol . 2024;35(suppl 2): S1032. [Mini oral presentation presented at: ESMO Congress 2024; September 13-17, 2024; Barcelona, Spain].

  View
• October, 2024

  Liang E, Yang D, Zhai Y, Yin Y, Li B, Wang H, Min P . P1550: Embryonic ectoderm development (EED) inhibitor APG-5918 improves chronic kidney disease- (CKD)-induced hemoglobin (Hb) insufficiency in preclinical models of anemia. HemaSphere . 2024;8(suppl 1): 2869-2870. [Poster presented at: 2024 EHA Congress; June 13-16, 2024; Madrid, Spain].

  View
• October, 2024

  Jabbour E, Jamy O, Koller PB, Oehler VG, Baer M, Lomaia E, Hunter AM, Cortes J, Uspenskaya O, Samarina S, Mukherjee S, Zherebtsova V, Shuvaev V, Turkina A, Davydkin I, Guo H, Chen Z, Fu T, Wang H, Jiang L, Wang C, Liang E, Xiong Y, Yang D, Zhai Y, Kantarjian H. P722: Olverembatinib overcomes ponatinib and asciminib resistance in patients (pts) with heavily pretreated chronic myeloid leukemia (CML) and Philadelphia-positive acute lymphoblastic leukemia (Ph⁺ ALL). HemaSphere . 2024;8(suppl 1): 1255-1256. [Poster presented at: 2024 EHA Congress; June 13-16, 2024; Madrid, Spain].

  View
• October, 2024

  Ailawadhi S, Chanan-Khan A, Yannakou C, Khouri J, Gibbs S, Chen Z, Guo H, Li M, Ahmad M, Wang C, Yang D, Zhai Y . P917: Lisaftoclax (APG-2575) combined with novel therapeutic regimens in patients (pts) with relapsed or refractory (R/R) multiple myeloma (MM) or immunoglobulin light-chain (AL) amyloidosis. HemaSphere . 2024;8(suppl 1): 1623-1624. [Poster presented at: 2024 EHA Congress; June 13-16, 2024; Madrid, Spain].

  View
• October, 2024

  Wang H, Wei X, Liang Y, Jiang Q, He W, Li Q, Weng J, Chen S, Chang C, Ma H, Xu Y, He Q, Chen Z, Liu L, Men L, Cong D, Zhang Z, Yang D, Zhai Y, Jin J. Safety and efficacy of lisaftoclax, a novel BCL-2 inhibitor, in combination with azacitidine in patients with treatment-naïve or relapsed or refractory acute myeloid leukemia. J Clin Oncol . 2024;42(suppl 16): 6541. [Poster presented at: 2024 ASCO Annual Meeting; May 31 - June 4, 2024; Chicago, IL].

  View
• October, 2024

  Qiu H, Zhou Z, Zhou Y, Chen J, Wan X, Li N, Tao K, Li Y, Wu X, Chen Z, Liu L, Yang C, Men L, Wang H, Liang E, Wang C, Lixin Jiang L, Yang D, Zhai Y, Xu R-H. Updated efficacy results of olverembatinib (HQP1351) in patients with tyrosine kinase inhibitor (TKI)-resistant succinate dehydrogenase (SDH)-deficient gastrointestinal stromal tumors (GIST) and paraganglioma. J Clin Oncol . 2024;42(suppl 16): 11502. [Oral presentation presented at: 2024 ASCO Annual Meeting; May 31 - June 4, 2024; Chicago, IL] .

  View
• October, 2024

  Ma Y, Zhao H, Chen J, Song Z, Zhao Y, Guo Y, Wu G, Yang H, Yu X, Gao F, Zhang R, Fang J, Lin X, Liu G, Yang C, Men L, Liang E, Yang D, Zhang L, Zhai Y. Updated study results of novel FAK/ALK/ROS1 inhibitor APG-2449 in patients (pts) with non-small-cell lung cancer (NSCLC) resistant to second-generation ALK inhibitors. J Clin Oncol . 2024;42(suppl 16): 3124. [Poster presented at: 2024 ASCO Annual Meeting; May 31 - June 4, 2024; Chicago, IL].

  View
• October, 2024

  Lasica M, Ailawadhi S, Fu C, Thomas SK, Wu D, Yi S, Siddiqi T, Yin Q, Allan JN, Chen W, Matous JV, Feng R, Chen Z, Yu M, Li M, He Z, Ahmad M, Wang H, Chanan-Khan A, Zhai Y. Updated efficacy and safety results of BCL-2 inhibitor lisaftoclax (APG-2575) alone or combined with ibrutinib or rituximab in patients (pts) with Waldenström macroglobulinemia (WM). J Clin Oncol . 2024;42(suppl 16): 7078. [Poster presented at: 2024 ASCO Annual Meeting; May 31 - June 4, 2024; Chicago, IL].

  View
• October, 2024

  Yu Z, Liang E, Liu D, Wu B, Yao X, Ji Y, Yang D, Zhai Y. Abstract 4569. APG-2449, a novel focal adhesion kinase (FAK) inhibitor, inhibits metastasis and enhances the antitumor efficacy of PEGylated liposome doxorubicin (PLD) in epithelial ovarian cancer (EOC). Cancer Res . 2024;84 (suppl 6): 4569. [Poster presented at: AACR Annual Meeting 2024; April 5-10, 2024; San Diego, CA].

  View
• October, 2024

  Yin Y, Yang Y, Liang E, Li B, Wang H, Yang D, Zhai Y. Abstract 3223: Embryonic ectoderm development (EED) inhibitor APG-5918 (EEDi-5273) and MDM2 inhibitor alrizomadlin (APG-115) synergistically inhibit tumor growth in preclinical models of prostate cancer (PCa). Cancer Res . 2024;84(suppl 6): 3223. [Poster presented at: AACR Annual Meeting 2024; April 5-10, 2024; San Diego, CA].

  View
• October, 2024

  Xiong Y, Liang E, Min P, Yu H, Wu B, Zhai G, Yang D, Zhai Y. Abstract 1971. Olverembatinib, a novel multikinase inhibitor, demonstrates superior antitumor activity in succinate dehydrogenase (SDH)-deficient neoplasms. Cancer Res . 2024; 2024;84(suppl 6): 1971. [Poster presented at: AACR Annual Meeting 2024; April 5-10, 2024; San Diego, CA].

  View
• October, 2024

  Xue H, Wang L, Ma Y, Hou C. Pharmacotherapy and cardiovascular challenges: a case report of olverembatinib-induced myocardial infarction with non-obstructive coronary arteries. BMC Cardiovasc Disord . 2024;24 332.

  View
• October, 2024

  Wang H, Yang Y, Chen Z, Fu L, Yu M, Jiang L, Wang C, Men L, Minto I, Yang D, Zhai Y. Pharmacokinetics of olverembatinib (HQP1351) in the presence of a strong CYP3A4 inhibitor (itraconazole) or inducer (rifampin) in healthy volunteers. Clin Transl Sci . 2024;17: e70021.

  View
• October, 2024

  Tang H, Jia W, Jia S, Dong R, Gao S, Feng J, Dong H, Gu H, Zhang T, Yuan R, Liu X, Cheng L, Zhou S, Gao G. A new chemotherapy-free regimen of olverembatinib in combination with venetoclax and dexamethasone for newly diagnosed Ph+ acute lymphoblastic leukemia: Preliminary outcomes of a prospective study. Am J Hematol . 2024;99: 1177-1179.

  View
• October, 2024

  Liu T, Wang C, Fu Y, Yang YP, Tan YH. Olverembatinib combined with inotuzumab ozogamicin in relapsed refractory Philadelphia chromosome-positive acute lymphoblastic leukemia: A case report. Medicine (Baltimore) 2024. 103: e38985.

  View
• October, 2024

  Liu FR, Wei XL, Feng WN, Zhao HY, Zhang Y, Wang ZQ, Zhang DS, Wang FH, Yang S, Pan W, Tian X, Men L, Wang H, Liang E, Wang C, Yang D, Zhai Y, Qiu MZ, Xu RH. Inhibitor of apoptosis proteins (IAP) inhibitor APG-1387 monotherapy or in combination with programmed cell death 1 (PD-1) inhibitor toripalimab in patients with advanced solid tumors: results from two phase I trials. ESMO Open 2024. 9: 103651.

  View
• July, 2024

  Yan Y, Qu S, Liu J, Li C, Yan X, Xu Z, Qin T, Jia Y, Pan L, Gao Q, Jiao M, Li B, Gale RP, Xiao Z. Olverembatinib for myeloid/lymphoid neoplasm associated with eosinophilia and FGFR1 rearrangement. Leuk Lymphoma 2023. 64: 1605-1610.

  View
• July, 2024

  Yang Z, Liu C, Hu Y, Liu H, Li J, Wu L, Liu Q, Zheng Y, Huang P, Wang Y. Tyrosine kinase inhibitors combined with venetoclax and azacytidine as an effective therapy for de novo lymphoid blast phase-chronic myeloid leukemia. Leuk Res 2023. 127: 107039.

  View
• July, 2024

  Xiang D, Zhao T, Wang J, Cao Y, Yu Q, Liu L, Yu H, Li X, Li N, Yi Y, Gong X. Determination of olverembatinib in human plasma and cerebrospinal fluid by an LC-MS/MS method: validation and clinical application. J Pharm Biomed Anal 2023. 230: 115382.

  View
• July, 2024

  Li X, Zhang J, Liu F, Liu T, Zhang R, Chen Y, Guo Y, Fang Y, Xu X, Pui CH, Zhu X. Olverembatinib Treatment in Pediatric Patients With Relapsed Philadelphia-Chromosome-Positive Acute Lymphoblastic Leukemia. Lymphoma Myeloma Leuk 2023. 23: 660-666.

  View
• July, 2024

  Tan X, Wen Q, Chen G, Wan K, Liu X, Ma YY, Wang MH, Zhang X, Zhang C. Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study. Anticancer Drugs 2023. 34: 599-604.

  View
• July, 2024

  Ding J, Li W. Case report: Olverembatinib monotherapy: the chemotherapy-free regimen for an elderly patient with relapsed Ph-positive acute lymphoblastic leukemia. Front Pharmacol 2023. 14: 1320641.

  View
• July, 2024

  Yin Z, Liao M, Yan R, Li G, Ou R, Liu Z, Zhong Q, Shen H, Zhu Y, Xie S, Zhang Q, Liu S, Huang J. Transcriptome- and metabolome-based candidate mechanism of BCR-ABL-independent resistance to olverembatinib in Philadelphia chromosome-positive acute lymphoblastic leukemia. Funct Integr Genomics 2023. 23: 53.

  View
• July, 2024

  Zhang T, Zhou H, Xu M, Qian C, Sun A, Wu D, Xue S. Combination venetoclax and olverembatinib (HQP1351) as a successful therapeutic strategy for relapsed/refractory (R/R) mixed-phenotype blast phase of chronic myeloid leukemia. Ann Hematol 2023. 102: 973-975.

  View
• July, 2024

  Liu C, Zhang X, Mao L, Qian J, Xiao F, Ye X, Wei J, Ye X, Jin J, Yu W. Olverembatinib in relapsed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: a study of 5 cases. Leuk Lymphoma 2023. 64: 1208-1211.

  View
• July, 2024

  Yi H, Yan X, Luo Q, Yuan L, Li B, Pan W, Zhang L, Chen H, Wang J, Zhang Y, Zhai Y, Qiu MZ, Yang DJ. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of gastric adenocarcinoma. J Exp Clin Cancer Res 2018. 37: 97.

  View
• July, 2024

  Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Fernandez-Salas E, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, Sun D, Stuckey J, Zhou Y, Chen J, Tang G, Wang S. EEDi-5285: An exceptionally potent, efficacious, and orally active small-molecule inhibitor of embryonic ectoderm development. J Med Chem 2020. 63: 7252-7267.

  View
• July, 2024

  Luo Q, Pan W, Zhou S, Wang G, Yi H, Zhang L, Yan X, Yuan L, Liu Z, Wang J, Chen H, Qiu M, Yang D, Sun J. A novel BCL-2 inhibitor APG-2575 exerts synthetic lethality with BTK or MDM2-p53 inhibitor in diffuse large B-cell lymphoma. Oncol Res 2020. 28: 331-344.

  View
• July, 2024

  Luo F, Lu FT, Qiu MZ, Zhou T, Ma WJ, Luo M, Zeng KM, Luo QY, Pan WT, Zhang L, Xia ZF, Zhang ZH, Cao JX, Zhao HY, Zhang L, Yang DJ. Gemcitabine and APG-1252, a novel small molecule inhibitor of BCL-2/BCL-XL, display a synergistic antitumor effect in nasopharyngeal carcinoma through the JAK-2/STAT3/MCL-1 signaling pathway. Cell Death Dis 2021. 12: 772.

  View
• July, 2024

  Zhao W, Yu D, Zhai Y, Sun SY. ALK inhibitors downregulate the expression of death receptor 4 in ALK-mutant lung cancer cells via facilitating Fra-1 and c-Jun degradation and subsequent AP-1 suppression. Neoplasia 2023. 42: 100908.

  View
• July, 2024

  Ailawadhi S, Chen Z, Huang B, Paulus A, Collins MC, Fu L, Li M, Ahmad M, Men L, Wang H, Davids MS, Liang E, Mekala DJ, He Z, Lasica M, Yannakou CK, Parrondo R, Glass L, Yang D, Chanan-Khan A, Yifan Zhai Y. Novel BCL-2 inhibitor lisaftoclax in relapsed or refractory chronic lymphocytic leukemia and other hematologic malignancies: first-in-human open-label trial. Clin Cancer Res 2024. 29: 2385-2393.

  View
• July, 2024

  Somaiah N, Paudyal B, Winkler RE, Van Tine BA, Hirbe AC. Malignant peripheral nerve sheath tumor, a heterogeneous, aggressive cancer with diverse biomarkers and no targeted standard of care: review of the literature and ongoing investigational agents. Target Oncol 2024.

  View
• July, 2024

  Pan W, Luo Q, Liang E, Shi M, Sun J, Shen H, Lu Z, Zhang L, Yan X, Yuan L, Zhou S, Yi H, Zhai Y, Qiu MZ, Yang D. Synergistic effects of Smac mimetic APG-1387 with anti-PD-1 antibody are attributed to increased CD3 + NK1.1 + cell recruitment secondary to induction of cytokines from tumor cells. Cancer Cell Int 2024. 24: 181.

  View
• July, 2024

  Lakhani NJ, Rasco D, Wang H, Men L, Liang E, Fu T, Collins MC, Min P, Yin Y, Davids MS, Yang D, Zhai Y. First-in-human study with preclinical data of BCL-2/BCL-xL inhibitor pelcitoclax in locally advanced or metastatic solid tumors. Clin Cancer Res 2024. 30: 506-521.

  View
• July, 2024

  Zhang X, Wen X, Peng R, Pan Q, Weng D, Ma Y, Zhang Y, Yang J, Men L, Wang H, Liang E, Wang C, Yang D, Zhang L, Zhai Y. A first-in-human phase I study of a novel MDM2/p53 inhibitor alrizomadlin in advanced solid tumors. ESMO Open 2024. 9: 103636.

  View
• July, 2024

  Luo F, Li H, Ma W, Cao J, Chen Q, Lu F, Qiu M, Zhou P, Xia Z, Zeng K, Zhan J, Zhou T, Luo Q, Pan W, Zhang L, Lin C, Huang Y, Zhang L, Yang D, Zhao H. The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation. Cell Mol Immunol 2024. 21: 60-79.

  View
• July, 2024

  Lipton JH. Maximizing the value of chronic myeloid leukemia management using tyrosine kinase inhibitors in the USA: potential determinants and consequences of healthcare resource utilization and costs, with proposed optimization approaches. Clin Drug Investig 2024. 41: 91-108.

  View
• June, 2023

  Rej RK, Wang C, Lu J, Wang M, Petrunak E, Zawacki KP, McEachern D, Yang CY, Wang L, Li R, Chinnaswamy K, Wen B, Sun D, Stuckey JA, Zhou Y, Chen J, Tang G, Wang S. Discovery of EEDi-5273 as an exceptionally potent and orally efficacious EED inhibitor capable of achieving complete and persistent tumor regression. J Med Chem 2021. 64: 14540-14556. DOI:10.1021/acs.jmedchem.1c01059.

  View
• June, 2023

  Senapati J, Sasaki K, Issa GC, Lipton JH, Radich JP, Jabbour E, Kantarjian HM. Management of chronic myeloid leukemia in 2023 – common ground and common sense. Blood Cancer J 2023. 13: 58. DOI:10.1038/s41408-023-00823-9.

  View
• March, 2023

  Zhang X, Xu X, Guan Y, Liang X, Liu H, Liu Z, Huang X, Xu Z, Sun J, Han X, Lu F, Wang P, Wang H, Xu L, Men L, Wang C, Yang D, Zhai Y, Hou J. First-in-human study of APG-1387, targeting inhibitor of apoptosis proteins, for the treatment of patients with chronic hepatitis B. [Oral presentation presented at: AASLD: The Liver Meeting; November 4-8, 2022; Washington, DC]. Hepatology . 76 (suppl 1)

  View
• January, 2023

  Zhao H, Chen J, Song Z, Zhao Y, Guo Y, Wu G, Ma Y, Zhou W, Yu X, Gao F, Dong Y, Zhang R, Yang C, Tian X, Wang H, Tu Y, Yu J, Sun X, Zhang L, Zhai Y. First-in-human phase I results of APG-2449, a novel FAK and third-generation ALK/ ROS1 tyrosine kinase inhibitor (TKI), in patients (pts) with second-generation TKI-resistant ALK/ROS1+ non–small cell lung cancer (NSCLC) or mesothelioma. [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): 9071. DOI:10.1200/JCO.2022.40.16_suppl.9071.

  View
• January, 2023

  Zhang L, Zhao H, Zhao Y, Cheng Y, Cui J, Ma Y, Yang C, Zhang J, Xu L, Yu J, Men L, Liang Z, Yang D, Zhai Y. Updated study results of pelcitoclax (APG-1252) in combination with osimertinib in patients (pts) with EGFR-mutant non–small cell lung cancer (NSCLC). [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): 9116. DOI:10.1200/JCO.2022.40.16_suppl.9116.

  View
• January, 2023

  Qin A, Kalemkerian GP, Mohindra NA, Patel JD, Karapetis CS, Carlisle JW, Sands J, Spira AI, Gao B, Amin H, Paudyal B, Frank G, Sun X, Xu Y, Wang C, Fu T, Winkler R, Liang Z, Yang D, Zhai Y. First-in-human study of pelcitoclax (APG-1252) in combination with paclitaxel in patients (pts) with relapsed/refractory small-cell lung cancer (R/R SCLC). J Clin Oncol 2022. 40 (suppl 16): e20612. DOI:10.1200/JCO.2022.40.16_suppl.e20612.

  View
• January, 2023

  Zhang X, Xu X, Guan Y, Liang X, Liu H, Liu Z, Huang X, Xu Z, Sun J, Han X, Lu F, Wang P, Wang H, Xu L, Men L, Wang C, Yang D, Zhai Y, Hou J. First-in-human study of APG-1387, targeting inhibitor of apoptosis proteins, for the treatment of patients with chronic hepatitis B. [Oral presentation presented at: AASLD: The Liver Meeting; November 4-8, 2022; Washington, DC]. Hepatology 2022. 76 (suppl 1): S30-S31. DOI:10.1002/hep.32697.

  View
• January, 2023

  Zhu S, Fang DD, Li Q, Yang D, Gu S, Wang S, Yang D, Zhai Y. Preclinical development of embryonic ectoderm development (EED) inhibitor APG-5918/EEDi-5273 for cancer therapy. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA]. Cancer Res 2022. 82 (suppl 12): 3939. DOI:10.1158/1538-7445.AM2022-3939.

  View
• January, 2023

  Tao R, Fang DD, Li Y, Zhai G, Zhou F, Wang Q, Deng J, Yang D, Zhai Y. FAK inhibitor APG-2449 and CDK4/6 inhibitor palbociclib synergistically suppress mesothelioma tumor growth via autophagy induction. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA]. Cancer Res 2022. 82 (suppl 12): 2563. DOI:10.1158/1538-7445.AM2022-2563.

  View
• January, 2023

  Gu S, Li Q, Li C, Wang Q, Fang DD, Wang S, Yang D, Zhai Y. Development of covalent KRASG12C inhibitor APG-1842 for the treatment of solid tumors. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA]. Cancer Res 2022. 82 (suppl 12): 2664. DOI:10.1158/1538-7445.AM2022-2664.

  View
• January, 2023

  Wang G, Liang E, Min P, Ge Y, Wu B, Yu H, Yang D, Zhai Y. MDM2-p53 inhibitor alrizomadlin (APG-115) enhances antitumor activity of pomalidomide in multiple myeloma (MM). [Poster presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. Blood 2022. 140 (suppl 1): 9953-9954. DOI:10.1182/blood-2022-162666.

  View
• January, 2023

  Kadia TM, Benton C, Erba HP, Gandhi M, Levy MY, Percival ME M, Ulrickson M, Yimer H, Yu M, Chen Z, Wang J, Li M, Ahmad M, Yang D, Zhai Y. Trial in progress: Phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine (AZA), in patients with relapsed/refractory acute myeloid leukemia (AML), chronic myelomonocytic leukemia (CMML), or myelodysplastic syndrome (MDS). Blood 2022. 140 (suppl 1): 11659-11660. DOI:10.1182/blood-2022-162627.

  View
• January, 2023

  McKean M, Tolcher AW, Reeves JA, Chmielowski B, Shaheen MF, Beck JT, Orloff MM, Somaiah N, Van Tine BA, Drabick JJ, Spira AI, O'Byrne K, Karapetis CS, Foresto SA, Movva S, Martinez J, Li M, Winkler R, Yang D, Zhai Y. Newly updated activity results of alrizomadlin (APG-115), a novel MDM2/p53 inhibitor, plus pembrolizumab: Phase 2 study in adults and children with various solid tumors. [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): 9517. DOI:10.1200/JCO.2022.40.16_suppl.9517.

  View
• January, 2023

  Pearson AT, Muzaffar J, Bellile E, Worden FP, Chung CH, Rosenberg A, Vokes E, Fidler MJ, Brenner JC, Zhai Y, Fu T, Winkler R, Swiecicki P. Phase I/II study of a novel MDM-2 inhibitor (APG-115) in TP53 wild type salivary gland cancers. [Poster presented at: the 34th EORTC-NCI-AACR Symposium; October 26-28, 2022; Barcelona, Spain]. Eur J Cancer 2022. 174 (suppl 1): S79-S80. DOI:10.1016/S0959-8049(22)01011-5.

  View
• January, 2023

  Wang G, Liang E, Tang C, Rui L, Min P, Lv J, Ge Y, Zhang F, Wang L, Shang J, Yang D, Zhai Y. MDM2 inhibitor alrizomadlin (APG-115) stabilizes p53 and synergizes with proteasome inhibitors in multiple myeloma. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA]. Cancer Res 2022. 82 (suppl 12): 5439. DOI:10.1158/1538-7445.AM2022-5439.

  View
• January, 2023

  Tang Q, Fang DD, Yu H, Wu B, Yin Y, Yang D, Zhai Y. Inhibition of MDM2-p53 interaction by alrizomadlin (APG-115) induces pyroptotic cell death in gasdermin E (GSDME)-expressing cancer cells. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA] . Cancer Res 2022. 82 (suppl 12): 2998. DOI:10.1158/1538-7445.AM2022-2998.

  View
• January, 2023

  Zhang Y, Chen W, Pathak A, Yang Y, Yang D, Zhai Y. Disease burden of chronic myeloid leukemia (CML) treatment failure in mainland China: a systematic literature review. [Poster presented at: Virtual ISPOR Europe 2021, Virtual Scientific Program; November 30-December 3, 2021]. Value in Health 2022. 25 (suppl 1): S32. DOI:10.1016/j.jval.2021.11.146.

  View
• January, 2023

  Zhang Y, Chen W, Xu Y, Pathak A, Lu Y, Yang D, Zhai Y. Impact of nilotinib reimbursement coverage on the use of tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in Chinese tertiary care hospitals: a retrospective analysis. [Poster presented at: ISPOR 2022, Virtual Scientific Program; May 15-18, 2022]. Value in Health 2022. 25 (suppl 7): S474. DOI:10.1016/j.jval.2022.04.971.

  View
• January, 2023

  Zhang Y, Chen W, Xu Y, Pathak A, Yang Y, Yang D, Zhai Y. Impact of an imatinib volume-based purchase policy (VBP) on the use of tyrosine kinase inhibitors (TKI) for chronic myeloid leukemia (CML) in Chinese tertiary care hospitals: a retrospective analysis. [Poster presented at: ISPOR 2022, Virtual Scientific Program; May 15-18, 2022]. Value in Health 2022. 25 (suppl 7): S477. DOI:10.1016/j.jval.2022.04.987.

  View
• January, 2023

  Jiang Q, Li Z, Qin Y, Hu Y, Li W, Liu X, Xu N, Zhang Y, Song Y, Meng L, Hong Z, Liu B, Li Y, Chen S, Xue M, Zhu H, Li H, Du X, Lou J, Zhang X, Liang Y, Dai YJ, Chen Z, Niu Q, Men L, Yang D, Zhai Y, Huang XJ. A five-year follow-up on safety and efficacy of olverembatinib (HQP1351), a novel third-generation BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia (CML) in China. [Oral presentation presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. Blood 2022. 140 (suppl 1): 198-199. DOI:10.1182/blood-2022-170868.

  View
• January, 2023

  Jiang Q, Li Z, Hou Y, Hu Y, Li W, Liu X, Xu N, Zhang Y, Song Y, Meng L, Hong Z, Liu B, Li Y, Chen S, Xue M, Zhu H, Li H, Du X, Lou J, Zhang X, Liang Y, Dai YJ, Chen Z, Niu Q, Men L, Yang D, Zhai Y, Huang XJ. Updated results of pivotal phase 2 trials of olverembatinib (HQP1351) in patients (Pts) with tyrosine kinase inhibitor (TKI)-resistant chronic- and accelerated-phase chronic myeloid leukemia (CML-CP and CML-AP) with T315I mutation. [Oral presentation presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. Blood 2022. 140 (suppl 1): 203-204. DOI:10.1182/blood-2022-170698.

  View
• January, 2023

  Jabbour E, Koller PB, Oehler VG, Jamy OH, Mukherjee S, Hunter AM, Baer MR, Beck JT, Chen Z, Guo H, Fu L, Men L, Wang H, Yang D, Zhai Y, Kantarjian H, Jiang L, Wang C. Olverembatinib (HQP1351) overcomes ponatinib resistance in patients with heavily pretreated/refractory chronic myeloid leukemia (CML) and Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). [Oral presentation presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. Blood 2022. 140 (suppl 1): 200-202. DOI:10.1182/blood-2022-162387.

  View
• January, 2023

  Qiu H, Zhou Z, Zhou Y, Wan X, Tao K, Li Y, Wu X, Liu L, Chen Z, Men L, Liang Z, Lu M, Jiang L, Yang D, Xu RH, Zhai Y. Promising antitumor activity of olverembatinib (HQP1351) in patients (pts) with tyrosine kinase inhibitor- (TKI-) resistant succinate dehydrogenase- (SDH-) deficient gastrointestinal stromal tumor (GIST). [Poster discussion presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): 11513. DOI:10.1200/JCO.2022.40.16_suppl.11513.

  View
• January, 2023

  Sun M, Qi J, Song Y, Zhou K, Liu H, Shen A, Geng L, Zhou F, Huang J, Chen Z, Zhang H, Lu M, Ahmad M, Men L, Yang D, Zhai Y, Wang J. Preliminary results of a phase 1 study of novel BCL-2 inhibitor lisaftoclax (APG-2575) in Chinese patients (pts) with relapsed or refractory (R/R) non-Hodgkin lymphomas (NHLs). [Poster presented at: the 30th European Hematology Association Hybrid; June 9-12, 2022​]. HemaSphere 2022. 6: 996-997. DOI:10.1097/01.HS9.0000847292.19961.d6.

  View
• January, 2023

  Davids MS, Chanan-Khan A, Mudenda B, Nogaieva L, Kriachok I, Usenko H, Ivanov V, Kyselova O, Perekhrestenko T, Muzhychuk I, Myasnikov A, Maslyak Z, Proidakov A, Uspenskaya O, Borisenkova E, Marlton P, Siddiqi T, Winter A, Lysa T, Bakirov B, Fu L, Chen Z, Yu M, Li M, Glass L, Ahmad M, Karpenko O, Osipov I, De A, Paudyal B, Wang H, Winkler R, Gabrail N, Ganju V, Konstantinova TS, Samoylova OS, Yang D, Zhai Y. Lisaftoclax (APG-2575) safety and activity as monotherapy or combined with acalabrutinib or rituximab in patients (pts) with treatment-naïve, relapsed or refractory chronic lymphocytic leukemia/small lymphocytic lymphoma (R/R CLL/SLL): initial data from a phase 2 global study. [Oral presentation presented at: the 64th ASH Annual Meeting and Exposition; December 10-13, 2022; New Orleans, LA]. Blood 2022. 140 (suppl 1): 2326-2328. DOI:10.1182/blood-2022-160386 .

  View
• January, 2023

  Kalinsky K, Tolcher AW, Wang S, Meric-Bernstam F, Winkler R, Li M, Sun X, Pan W, Paudyal B, Liang Z, Lu M, Yang D, Zhai Y. Phase 1b/2 study of BCL-2 inhibitor lisaftoclax (APG-2575) safety and tolerability when administered alone or combined with a cyclin-dependent kinase 4/6 (CDK4/6) inhibitor in patients with estrogen receptor-positive (ER⁺) breast cancer or advanced solid tumors​. [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): TPS1122. DOI:10.1200/JCO.2022.40.16_suppl.TPS1122.

  View
• January, 2023

  Li J, Zhou K, Nian W, Cui G, Wang J, Zhang X, Cen H, Li F, Yi S, Feng R, Xu C, Qian W, Liu L, Li C, Zhao X, Chen Z, Qiao J, Zhang H, Ahmad M, Zhai Y. A phase Ib/II study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma (R/R CLL/SLL). [Poster presented at: 2022 ASCO Annual Meeting; June 3-7, 2022; Chicago, IL]. J Clin Oncol 2022. 40 (suppl 16): 7543. DOI:10.1200/JCO.2022.40.16_suppl.7543.

  View
• January, 2023

  Deng J, Zhang K, Tang Q, Huang X, Wang Q, Li N, Fang DD, Yang D, Zhai Y. Co-targeting MDM2-p53 and BCL-2 apoptosis pathways overcomes resistance conferred by acquired BCL-2 gene mutations in preclinical models. [Poster presented at: AACR Annual Meeting 2022; April 8-13, 2022; New Orleans, LA]. Cancer Res 2022. 82 (suppl 12): 3964. DOI:10.1158/1538-7445.AM2022-3964.

  View
• January, 2023

  Zhai Y, Tang Q, Fang D, Deng J, Zhang K, Wang Q, Yin Y, Fu C, Xue SL, Li N, Zhou F, Yang D. Lisaftoclax in combination with alrizomadlin overcomes venetoclax resistance in acute myeloid leukemia and acute lymphoblastic leukemia: preclinical studies. Clin Cancer Res 2023. 29: 183-196.

  View
• January, 2023

  Yao W, Bai L, Wang S, Zhai Y, Sun SY. Mcl-1 levels critically impact the sensitivities of human colorectal cancer cells to APG-1252-M1, a novel Bcl-2/Bcl-XL dual inhibitor that induces Bax-dependent apoptosis. Neoplasia 2022. 22: 100798. DOI:10.1016/j.neo.2022.100798.

  View
• January, 2023

  Selt F, Sigaud R, Valinciute G, Sievers P, Zaman J, Alco C, Schmid S, Peterziel H, Tsai JW, Guiho R, Martínez-Barbera JP, Pusch S, Deng J, Zhai Y, van Tilburg CM, Schuhman MU, Damaty AEL, Bandopadhayay P, Herold-Mende C, von Deimling A, Pfister SM, Montero J, Capper D, Oehme I, Sahm F, Jones DTW, Witt O, Milde T. BH3 mimetics targeting BCL-XL impact the senescent compartment of pilocytic astrocytoma. Neuro-Oncol 2022. DOI:10.1093/neuonc/noac199.

  View
• January, 2023

  Qian L, Vallega KA, Yao W, Wang D, Zhai Y, He X, Sunet SY. Therapeutic potential of the novel Bcl-2/Bcl-XL dual inhibitor, APG1252, alone or in combination against non-small cell lung cancer. Mol Carcinog 2022. 61: 1031-1042. DOI:10.1002/mc.23458.

  View
• January, 2023

  Ma G, Deng Y, Qian L, Vallega KA, Zhang G, Deng X, Owonikoko TK, Ramalingam SS, Fang DD, Zhai Y, Sun SY. Overcoming acquired resistance to third-generation EGFR inhibitors by targeting activation of intrinsic apoptotic pathway through Mcl-1 inhibition, Bax activation, or both. Oncogene 2022. 41: 1691-1700. DOI:10.1038/s41388-022-02200-5.

  View
• January, 2023

  Fang DD, Tao R, Wang G, Li Y, Zhang K, Xu C, Zhai G, Wang Q, Wang J, Tang C, Min P, Xiong D, Chen J, Wang S, Yang D, Zhai Y. Discovery of a novel ALK/ROS1/FAK inhibitor, APG-2449, in preclinical non-small cell lung cancer and ovarian cancer models. BMC Cancer 2022. 22: 752. DOI:10.1186/s12885-022-09799-4.

  View
• January, 2023

  Wei W, Huang S, Ling Q, Mao S, Qian Y, Ye W, Li F, Pan J, Lin X, Huang J, Huang X, Zhai Y, Sun J, Jin J. Homoharringtonine is synergistically lethal with BCL-2 inhibitor APG-2575 in acute myeloid leukemia. J Transl Med 2022. 20: 299. DOI:10.1186/s12967-022-03497-2.

  View
• January, 2023

  Deng J, Paulus A, Fang DD, Manna A, Wang G, Wang H, Zhu S, Chen J, Min P, Yin Y, Dutta N, Halder N, Ciccio G, Copland JA, Miller J, Han B, Bai L, Liu L, Wang M, McEachern D, Przybranowski S, Yang CY, Stuckey JA, Wu D, Li C, Ryan J, Letai A, Ailawadhi S, Yang D, Wang S, Chanan-Khan A, Zhai Y. Lisaftoclax (APG-2575) is a novel BCL-2 inhibitor with robust antitumor activity in preclinical models of hematologic malignancy. Clin Cancer Res 2022. 28: 5455-5468. DOI:10.1158/1078-0432.CCR-21-4037.

  View
• January, 2023

  Zhang Y, Chen W, Pathak A, Yang Y, Yang D, Zhai Y. Burden of tyrosine kinase inhibitor failure in Chinese chronic myeloid leukemia patients: a systematic literature review. J Comp Eff Res 2022. 11: 621-637. DOI:10.2217/cer-2022-0032.

  View
• January, 2023

  Yu Z, Lei Z, Yao X, Wang H, Zhang M, Hou Z, Li Y, Zhao Y, Li H, Liu D, Zhai Y. Potential drug-drug interaction of olverembatinib (HQP1351) using physiologically based pharmacokinetic models. Front Pharmacol 2022. 13: 1065130. DOI:10.3389/fphar.2022.1065130.

  View
• January, 2023

  Tan X, Qin W, Guo C, Wan K, Liu X, Ma YY, Wang MH, Zhang X, Zhang C. Novel third-generation tyrosine kinase inhibitor for newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia: a case study. Anti-Cancer Drugs 2022. DOI:10.1097/CAD.0000000000001455.

  View
• January, 2023

  Jiang Q, Li Z, Qin Y, Li W, Xu N, Liu B, Zhang Y, Meng L, Zhu H, Du X, Chen S, Liang Y, Hu Y, Liu X, Song Y, Men L, Chen Z, Niu Q, Wang H, Lu M, Yang D, Zhai Y, Huang X. Olverembatinib (HQP1351), a well-tolerated and effective tyrosine kinase inhibitor for patients with T315I-mutated chronic myeloid leukemia: results of an open-label, multicenter phase 1/2 trial. J Hematol Oncol 2022. 15: 113. DOI:10.1186/s13045-022-01334-z.

  View
• January, 2023

  Chan M, Holland EC, Gujral TS. Olverembatinib inhibits SARS-CoV-2-Omicron variant-mediated cytokine release. EMBO Mol Med 2022. 14: e15919. DOI:10.15252/emmm.202215919.

  View
• February, 2022

  Dhillon S. Olverembatinib: First Approval. Drugs 2022. 82: 469-475. DOI:10.1007/s40265-022-01680-9.

  View
• January, 2022

  Fang DD, Zhu H, Tang Q, Wang G, Min P, Wang Q, Li N, Yang D, Zhai Y. FLT3 inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor lisaftoclax (APG-2575) in preclinical models of FLT3-ITD mutant acute myeloid leukemia. Transl Oncol 2022. 15: 101244. DOI:10.1016/j.tranon.2021.101244.

  View
• December, 2021

  Wang G, Liang E, Ming P et al. Antitumor Activity of Dual BCL-2/BCL-Xl Inhibitor Pelcitoclax (APG-1252) in Natural Killer/T-Cell Lymphoma (NK/TCL). American Society of Hematology Annual Meeting 2021. Blood 2021; 138 (Supplement 1): 2062 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152207.

  View
• December, 2021

  Qian J, Shi D, Li Z, et al. Updated Results of Pivotal Phase 2 Trials of Olverembatinib (HQP1351) in Patients (Pts) with Tyrosine Kinase Inhibitor (TKI)-Resistant BCR-ABL1 T315I-Mutated Chronic- and Accelerated-Phase Chronic Myeloid Leukemia (CML-CP and CML-AP). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3598 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-153937.

  View
• December, 2021

  Qian J, Shi D, Li Z, et al. Updated Safety and Efficacy Results of Phase 1 Study of Olverembatinib (HQP1351), a Novel Third-Generation BCR-ABL Tyrosine Kinase Inhibitor (TKI), in Patients with TKI-Resistant Chronic Myeloid Leukemia (CML). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 311 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-153065.

  View
• December, 2021

  Jabbour EJ, Kantarjian H, Issa GC, et al. Trial in Progress: Phase 1b Bridging Study of the Pharmacokinetics (PK), Safety, and Efficacy of Orally Administered Olverembatinib (HQP1351) in Patients with Refractory Chronic Myeloid Leukemia (CML) and Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph⁺ ALL). Blood . 2021;138 (suppl 1): 2551.

  View
• December, 2021

  Sun M, Qi J, Chen Z, et al. A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3730. December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152235.

  View
• December, 2021

  Sun M, Qi J, Chen Z, et al. A Phase 1 Study to Evaluate the Safety, Pharmacokinetics (PK) and Pharmacodynamics (PD) of Lisaftoclax (APG-2575), a Novel BCL-2 Inhibitor (BCL-2i), in Patients (pts) with Certain Relapsed or Refractory (R/R) Hematologic Malignancies (HMs). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 3730 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152235.

  View
• December, 2021

  Davids MS, Siddiqi T, Chanan-Khan A, et al. Trial in Progress: Phase 1b Study of Lisaftoclax (APG-2575) As a Single Agent or Combined with Other Therapeutic Agents in Patients with Relapsed and/or Refractory Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (R/R CLL/SLL). American Society of Hematology annual meeting 2021. Blood 2021; 138 (Supplement 1): 1554 December 11-14, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-152811.

  View
• November, 2021

  Zhai Y, et al. Trial in progress: A phase 1b/2 study of alrizomadlin (APG-115), alone or combined with 5-azacitidine, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).. Presented at the Society for Immunotherapy of Cancer annual meeting 2021 Journal for ImmunoTherapy of Cancer 2021. . 9: Abstract 445 DOI:doi: 10.1136/jitc-2021-SITC2021.445.

  View
• November, 2021

  Zhai Y, et al. Trial in progress: A phase 1b study of alrizomadlin, alone or plus 5-azacitidine or cytarabine, in pts with relapsed/refractory acute myeloid leukemia and relapsed higher-risk myelodysplastic syndrome.. Presented at the Society for Immunotherapy of Cancer annual meeting 2021. Journal for ImmunoTherapy of Cancer 2021 November 10-14, 2021. 9: Abstract 450

  View
• November, 2021

  Fu C, Chen Z, Li W, et al. Trial in Progress: Phase 1b/2 Open-Label Study of Lisaftoclax (APG-2575) Monotherapy or in Combination with Lenalidomide/Dexamethasone in Patients with Relapsed or Refractory Multiple Myeloma (R/R MM). Blood 2021; 138 (Supplement 1): 4764 November 5, 2021. DOI:doi: https://doi.org/10.1182/blood-2021-151631.

  View
• October, 2021

  Fang DD, Tang Q, Wang Q, et al. Collaborative crosstalk between two apoptosis pathways drives synergy of dual inhibition of BCL-2/MDM2 in preclinical models of neuroblastoma [abstract]. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 2021;20(12 Suppl):Abstract nr P209 Oct 7-10, 2021. DOI:https://doi.org/10.1158/1535-7163.TARG-21-P209.

  View
• October, 2021

  Fang DD, Tang Q, Wang Q, et al. Synergistic antitumor activity of lisaftoclax (APG-2575) and alrizomadlin (APG-115) through dual targeting of BCL-2/MDM2-P53 apoptotic pathways in preclinical models of acute myeloid leukemia [abstract]. AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics. Mol Cancer Ther 2021; 20(12 Suppl): Abstract nr P208. Oct 7-10, 2021. DOI:https://doi.org/10.1158/1535-7163.TARG-21-P208.

  View
• September, 2021

  Zhang L, Zhao H, Ma Y, et al. Phase 1b Study of Pelcitoclax (APG-1252) in combination with osimertinib in patients with EGFR TKI-resistant NSCLC Virtual. 2021 World Conference on Lung Cancer. Journal of Thoracic Oncology 2021 September 8-14, 2021. DOI:https://doi.org/10.1016/j.jtho.2021.08.115.

  View
• June, 2021

  Swiecicki P, et al. Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma. Presented at the American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology June 4-8, 2021. 39, no. 15_suppl: Abstract TPS6094

  View
• June, 2021

  Tolcher AW, et al. Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs. Oral presentation. Presented at the American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology June 4-8, 2021. no. 15_suppl: Abstract 2506 DOI:DOI: 10.1200/JCO.2021.39.15_suppl.2506.

  View
• June, 2021

  Qin A, Kalemkerian GP, Patel JD, et al. Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC). American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology 39, no. 15_suppl: Abstract TPS8589 June 4-8, 2021.

  View
• June, 2021

  Ailawadhi S, Chanan-Khan AA, Chen Z, et al. First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs). American Society of Clinical Oncology (ASCO) annual meeting 2021. Journal of Clinical Oncology 39, no. 15_suppl: Abstract 7502 June 4-8, 2021. DOI:DOI: 10.1200/JCO.2021.39.15_suppl.7502.

  View
• May, 2021

  Fang DD, Tang Q, Kong Y, Rong T, Wang Q, Li N, Fang X, Gu J, Xiong D, Yin Y, Deng J, Yang D, Zhai Y. MDM2 inhibitor APG-115 exerts potent antitumor activity and synergizes with standard-of-care agents in preclinical acute myeloid leukemia models. Cell Death Discovery 2021. 7: 90. DOI:10.1038/s41420-021-00465-5.

  View
• April, 2021

  Tao R, Fang DD, Li Y, et al. Focal adhesion kinase (FAK) inhibitor APG-2449 sensitizes ovarian tumors to chemotherapy via CD44 downregulation. The American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 968. April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-968.

  View
• April, 2021

  Li Q, Fang DD, Li Z, et al. Therapeutic potential of inhibitor of apoptosis protein (IAP) inhibitor APG-1387 combined with DR5 agonist monoclonal antibody (mAb) CTB-006 in preclinical models of solid tumors.. The American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract 1924 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1924.

  View
• April, 2021

  Guo Y, Deng J, Zhang L, et al. Targeting BCL-xL addiction with APG-1252 (pelcitoclax) to overcome apoptotic blockade in neuroendocrine neoplasm (NEN). American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract 984 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-984.

  View
• April, 2021

  Wang G, Lv J, Tang C, et al. ATP-site inhibitor olverembatinib, HQP1351, enhanced the effect of allosteric inhibitor on the resistance conferred by the compound mutations of BCR-ABL. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 1463 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1463.

  View
• April, 2021

  Fang DD, Zhu H, Tang Q, et al. FMS-like tyrosine kinase 3 (FLT3) inhibition by olverembatinib (HQP1351) downregulates MCL-1 and synergizes with BCL-2 inhibitor APG-2575 in preclinical models of FLT3-mutant acute myeloid leukemia (AML). American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81 (13_Supplement): Abstract 1096 April 10-15 and May 17-21, 2021 (Virtual). DOI:https://doi.org/10.1158/1538-7445.AM2021-1096.

  View
• April, 2021

  Fang DD, Tang Q, Kong Y, et al. BCL-2 inhibitor APG-2575 and homoharringtonine (HHT) synergistically induces apoptosis and inhibits tumor growth in preclinical models of acute myeloid leukemia and myelodysplastic syndromes (AML/MDS) [abstract]. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl): Abstract nr 981 Apr 10-15 and May 17-21, 2021. DOI:https://doi.org/10.1158/1538-7445.AM2021-981.

  View
• April, 2021

  Deng J, Fang DD, Tao R, et al. Inhibition of BCL-2 (by APG-2575) and CDK4/6 synergistically induces cell cycle arrest and apoptosis in ER+ breast cancer [abstract]. American Association for Cancer Research Annual Meeting 2021. Cancer Res 2021;81(13_Suppl):Abstract nr 976. Apr 10-15 and May 17-21, 2021 . DOI:https://doi.org/10.1158/1538-7445.AM2021-976 .

  View
• May, 2020

  Tolcher AW, et al. A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. Abstract 20. Ann Oncol 2019. 30 (Supplement 1) i2-i3. DOI:10.1093/annonc/mdz027.

  View
• December, 2019

  Jiang Q, Huang X, Chen Z, et al. An updated safety and efficacy results of phase 1 study of HQP1351, a novel 3rd- generation of BCR-ABL tyrosine kinase inhibitor (TKI), in patients with TKI-resistant chronic myeloid leukemia. American Society of Hematology Annual Meeting. Blood 2019; 134 (Supplement_1): 493. December 8, 2019. Abstract 493 DOI:doi: https://doi.org/10.1182/blood-2019-124295.

  View
• December, 2019

  Ailawadhi S, Alegria VR, Ahmed S, et al. Phase I study of a novel Bcl-2 inhibitor, AT-101 in combination with lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma (RRMM). American Society of Hematology Annual Meeting. Blood 2019; 134 (Supplement_1): 3137 December 8, 2019. Abstract 3137 DOI:doi: https://doi.org/10.1182/blood-2019-128610.

  View
• November, 2019

  Fang DD, et al. MDM2 inhibitor APG-115 synergizes with PD-1 blockade through enhancing antitumor immunity in the tumor microenvironment. J Immunother Cancer November 28, 2019. 7 327. DOI:10.1186/s40425-019-0750-6.

  View
• November, 2019

  Deng J, Mao T, Huang X, et al. A novel BCL-2/BCL-Xl dual inhibitor overcomes ibrutinib-resistance conferred by the upregulation of integrin pathway and BCL-Xl. Blood 2019;134(Supplement 1): 2573 November 13, 2019. Abstract 2573

  View
• November, 2019

  Wang G, Min P, Tang C, et al. The inhibition of MDM2 by new antagonist APG-115 triggers apoptosis in p53 wild-type cancer cells in both in vitro and in vivo models. New Horizons in Cancer Research: Delivering Cures Through Cancer Science (AACR). . Poster presentation #2017

  View
• October, 2019

  Liu Q, et al. Preclinical development of HQP1351, a multikinase inhibitor targeting a broad spectrum of mutant KIT kinases, for the treatment of imatinib-resistant gastrointestinal stromal tumors. Cell Biosci 2019. 9 88. DOI:10.1186/s13578-019-0351-6.

  View
• July, 2019

  Fang DD, et al. BCL-2 selective inhibitor APG-2575 synergizes with BTK inhibitor in preclinical xenograft models of follicular lymphoma and diffuse large B-cell lymphoma. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl): Abstract 2058. DOI:10.1158/1538-7445.AM2019-2058 .

  View
• July, 2019

  Yan X, et al. A novel BCL-2/BCL-XL inhibitor APG-1252-12A as a potential therapeutic strategy for gastric carcinoma. Abstract 2054. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl) Abstract 2054. DOI:10.1158/1538-7445.AM2019-2054.

  View
• July, 2019

  Deng J, et al. Predicting drug sensitivity to a novel BCL-2 and BCL-XL dual inhibitor in solid tumor PDX trials. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019: Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl) Abstract 2503. DOI:10.1158/1538-7445.AM2019-2503.

  View
• July, 2019

  Fang DD, et al. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. Abstract 3192. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA. Cancer Res July 1, 2019. 79(13 Suppl) Abstract 3192. DOI:10.1158/1538-7445.AM2019-3192.

  View
• June, 2019

  Zhang X, Wen X, Yang C et al. A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. American Society of Clinical Oncology 2019 Annual Meeting. J Clin Oncol 2019;37(15 Suppl): Abstract 3124 June 1, 2019. DOI:DOI: 10.1200/JCO.2019.37.15_suppl.3124.

  View
• June, 2019

  Rasco DW, Li Y, Tang Y, et al. A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors. American Society of Clinical Oncology . J Clin Oncol 2019;37(15 Suppl):3125. NCT03386526 June 1, 2019. Abstract 3125

  View
• May, 2019

  Rasco DW, Lakhani NJ, Li Y, et al. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. J Clin Oncol 2019;37(15 suppl): 3126. NCT02935907 May 26, 2019. Abstract 3126

  View
• May, 2019

  Rasco DW, et al. A phase I study of a novel IAP inhibitor APG-1387 as a monotherapy or in combination with pembrolizumab in treatments of patients with advanced solid tumors. Abstract 3125. J Clin Oncol 2019. 37(15 Suppl) 3125. DOI:10.1200/JCO.2019.37.15_suppl.3125 .

  View
• May, 2019

  Zhang X, et al. A phase I study of a novel MDM2-P53 antagonist APG-115 in Chinese patients with advanced soft tissue sarcomas. J Clin Oncol 2019. 37(15 Suppl): Abstract 3124. DOI:10.1200/JCO.2019.37.15_suppl.3124.

  View
• May, 2019

  Rasco DW, et al. A phase I study of a novel MDM2 antagonist APG-115 in patients with advanced solid tumors. J Clin Oncol . 37(15 suppl). Abstract 3126 DOI:10.1200/JCO.2019.37.15_suppl.3126 .

  View
• April, 2019

  Zhang L, Qiuyun L, Xianglei Y et al. A novel small molecule inhibitor of MDM2-p53 (APG-115) has antitumor activity in gastric adenocarcinoma. Proceedings of the American Association for Cancer Research (AACR) Annual Meeting 2019. Cancer Res 2019;79(13 Suppl) March 29 to April 3, 2019. Abstract 2061

  View
• April, 2019

  Fang DD, Zhai G, Xu C, et al. MDM2 inhibitor APG-115 synergizes with CDK4/6 inhibitors in a patient-derived xenograft model of dedifferentiated liposarcoma. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79 (13 Suppl) March 29 to April 3, 2019. Abstract 1253

  View
• April, 2019

  Fang DD, Tang Q, Kong Y, et al. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl) March 29 to April 3, 2019. Abstract 3192

  View
• March, 2019

  Luo Y, Zhou S-N, Pao W-T, et al. FAK blockade enhances antitumor effect of BTK inhibitor in esophageal squamous cell carcinoma via EGFR-ERK-Akt pathway inhibition. American Association for Cancer Research Annual Meeting 2019. American Association for Cancer Research Annual Meeting March 31, 2019. 60:78-79 DOI:https://doi.org/10.1158/1538-7445.AM2019-309.

  View
• March, 2019

  Fang DD, et al. Synergistic effect of BCL-2 inhibitor APG-2575 and CDK9 inhibitor in acute myeloid leukemia and DLBCL preclinical tumor models. Proceedings of the American Association for Cancer Research Annual Meeting 2019; March 29 to April 3, 2019; Atlanta, GA USA. Cancer Res 2019. 79(13 Suppl): Abstract 3068 DOI:10.1158/1538-7445.AM2019-3068 .

  View
• March, 2019

  Deng J, Huang X, Zhai G, et al. Predicting drug sensitivity to a novel BCL-2 and BCL-xL dual inhibitor in solid tumor PDX trials. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl): Abstract 2503 March 29 - April 3, 2019.

  View
• March, 2019

  Yuan L, Pan W, Zhou S, et al. FAK inhibition reduces tumor infiltration of Tregs via restricting CCL5 release and boosts the present therapeutic regimen for BRAFV600E-mutated colorectal carcinoma. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl):Abstract 3958 March 29 - April 3, 2019 . DOI:https://doi.org/10.1158/1538-7445.AM2019-3958.

  View
• March, 2019

  Wang G, Fang DD, Min P, et al. Novel FAK/ALK/ROS1 inhibitor APG-2449 synergizes with osimertinib in preclinical xenograft models of EGFR-mutant NSCLC. American Association for Cancer Research Annual Meeting 2019 . Cancer Res 2019;79(13 Suppl): Abstract 2204. March 29 - April 3, 2019. Poster Session PO. ET06-11. Abstract No. 19-A-2864. DOI:https://doi.org/10.1158/1538-7445.AM2019-2204.

  View
• March, 2019

  Fang DD, Tang Q, Kong Y. Activation of p53 in the tumor microenvironment by MDM2 inhibitor APG-115 synergizes with PD-1 blockade independently of p53 status of tumor cells. American Association for Cancer Research Annual Meeting 2019. Cancer Res 2019;79(13 Suppl): Abstract 3192. March 29 - April 3, 2019.

  View
• February, 2019

  Tolcher AW, Fang DD, Li Y, et al. A phase Ib/II study of APG-115 in combination with pembrolizumab in patients with unresectable or metastatic melanomas or advanced solid tumors. European Society for Medical Oncology Targeted Anticancer Therapies International Congress 2019. Ann Oncol 2019;30 (Supplement 1):i2–i3 February 25-27, 2019. Abstract 20 DOI:doi: https://doi.org/10.1093/annonc/mdz027. NCT03611868.

  View
• December, 2018

  Deng J, Yin Y, Mao T, et al. Probing distinct oncogene addiction by novel BCL-2 inhibitors. 60th American Society of Hematology (ASH) Annual Meeting. Blood 2018;132(Suppl 1): 2616. Poster 2616 December 1-4, 2018.

  View
• December, 2018

  Jiang Q, Huang XJ, Chen Z, et al. Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: preliminary results of phase I study. 60th American Society of Hematology Annual Meeting. Blood 2018;132(Supplement 1):791. December 1-4, 2018.

  View
• December, 2018

  Deng J, Yin Y, Mao T et al. Probing distinct oncogene addiction by novel BCL-2 inhibitors. 60th American Society of Hematology (ASH) Annual Meeting. Blood 2018;132(Suppl 1) December 1-4, 2018. Poster 2616 DOI:doi: https://doi.org/10.1182/blood-2018-99-119816.

  View
• December, 2018

  Wu Y, et al. A phase I study of novel BCL-2/BCL-XL inhibitor APG-1252 in patients with advanced SCLC or other solid tumor. Abstract OA12. J Thorac Oncol 2018. 132(Supplement 1) S1048-S1049. DOI:10.1016/j.jtho.2018.10.022.

  View
• November, 2018

  Deng J, et al. Probing distinct oncogene addiction by novel BCL-2 inhibitors. Blood 2018. 132(Suppl 1) 2616. DOI:10.1182/blood-2018-99-119816 .

  View
• November, 2018

  Jiang Q, et al. Safety and efficacy of HQP1351, a 3rd generation oral BCR-ABL inhibitor in patients with tyrosine kinase inhibitor-resistant chronic myelogenous leukemia: preliminary results of phase I study. Blood 2018. 132(Supplement 1) 791. DOI:10.1182/blood-2018-99-119142 .

  View
• November, 2018

  Deng J, et al. Probing distinct oncogene addiction by novel BCL-2 inhibitors. Blood November 29, 2018. 132(Suppl 1) Abstract 2616. DOI:10.1182/blood-2018-99-119816.

  View
• November, 2018

  Chen Z, et al. The SMAC mimetic APG-1387 sensitizes immune-mediated cell apoptosis in hepatocellular carcinoma. Front Pharmacol 2018. 9 1298. DOI:10.3389/fphar.2018.01298.

  View
• October, 2018

  Liu H, et al. Targeting cIAPs, a new option for functional cure of chronic hepatitis B infection. Virol Sin 2018. 33 459-461. DOI:10.1007/s12250-018-0062-x.

  View
• September, 2018

  Luo Q, Wang G, Yi H et al. Inhibitors of anti-apoptotic BCL-2 family proteins are effective in non-Hodgkin’s lymphoma. Chinese Society of Clinical Oncology (CSC0) 18th annual meeting. .

  View
• September, 2018

  Pan W, Miaozhen Q, Fang DD, et al. The multi-faceted immunomodulatory function of Smac mimetic APG-1387 and its application in cancer immunotherapy. Chinese Society of Clinical Oncology (CSC0) 18th Annual Meeting. .

  View
• September, 2018

  Luo Q, Wang G, Yi H, et al. Inhibitors of anti-apoptotic BCL-2 family proteins are effective in non-Hodgkin’s lymphoma. Chinese Society of Clinical Oncology (CSC0) 18th Annual Meeting. .

  View
• August, 2018

  Pan W, et al. A novel SMAC mimetic APG-1387 exhibits dual antitumor effect on HBV-positive hepatocellular carcinoma with high expression of cIAP2 by inducing apoptosis and enhancing innate anti-tumor immunity. Biochem Pharmacol 2018. 154 127-135. DOI:10.1016/j.bcp.2018.04.020.

  View
• July, 2018

  Wang GF, et al. Targeting BCL-2 and BCL-XL with a novel dual inhibitor APG-1252 triggers cell death and inhibits tumor growth in small cell lung cancer models. Proceedings of the American Association for Cancer Research Annual Meeting; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl) Abstract 307. DOI:10.1158/1538-7445.AM2018-307.

  View
• July, 2018

  Luo Q-Y, et al. Targeting the anti-apoptotic BCL-2 family protein provides an effective and precise therapeutic strategy for NHL. Proceedings of the American Association for Cancer Research Annual Meeting; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl) Abstract 301. DOI:10.1158/1538-7445.AM2018-301.

  View
• June, 2018

  Xu R, et al. A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors. J Clin Oncol 2018. 36(15_suppl) 2593. DOI:10.1200/JCO.2018.36.15_suppl.2593 .

  View
• June, 2018

  Lakhani NL, et al. A phase I study of novel dual BCL-2/BCL-XL inhibitor APG-1252 in patients with advanced small cell lung cancer (SCLC) or other solid tumor. J Clin Oncol June 1, 2018. 36(Suppl 15) Abstract 2594. DOI:10.1200/JCO.2018.36.15_suppl.2594.

  View
• May, 2018

  Yi H, et al. A novel small molecule inhibitor of MDM2-p53 (APG-115) enhances radiosensitivity of adenocarcinoma. J Exp Clin Cancer Res 2018. 37 97. DOI:10.1186/s13046-018-0765-8.

  View
• April, 2018

  Pan W, Fang DD, Wang G, et al. Smac mimetics APG-1387 synergizes with immune checkpoint inhibitors in preclinical models. American Association for Cancer Research Annual Meeting 2018. Cancer Res 2018;78(13 Suppl): Abstract 1754 April 14-18, 2018.

  View
• April, 2018

  Yi H-J, Yan X-L, Luo Q-Y et al. A novel MDM2-p53 antagonist APG-115 induces p53-mediated apoptosis and enhances radiosensitivity in colorectal cancer. American Association for Cancer Research Annual Meeting. Cancer Res 2018;78(13 Suppl) April 14-18, 2018. Abstract 314

  View
• April, 2018

  Wang G, et al. HQP1351, a novel multikinase inhibitor in clinical development, overcomes drug resistance for the treatment of gastrointestinal stromal tumors in preclinical models. Proceedings of the American Association for Cancer Research Annual Meeting 2018; April 14‒18, 2018; Chicago, IL USA. Cancer Res 2018. 78(13 Suppl): Abstract 1979 DOI:10.1158/1538-7445.AM2018-1979.

  View
• March, 2018

  Li BX, et al. Novel smac mimetic APG-1387 elicits ovarian cancer cell killing through TNF-alpha, ripoptosome and autophagy mediated cell death pathway. J Exp Clin Cancer Res 2018. 37 53. DOI:10.1186/s13046-018-0703-9.

  View
• June, 2017

  Wang G, Yang D, Luo Q, et al. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins Bcl-2/Bcl-xl in HL-60 cells. Int J Oncol 2017;51:563-72 June 6, 2017.

  View
• June, 2017

  Wang G, et al. APG-1252-12A induces mitochondria-dependent apoptosis through inhibiting the antiapoptotic proteins BCL-2/BCL-xl in HL-60 cells. Int J Oncol 2017. 51 563-572. DOI:10.3892/ijo.2017.4028.

  View
• April, 2017

  Chen H, et al. Restoration of p53 using the novel MDM2-p53 antagonist APG115 suppresses dedifferentiated papillary thyroid cancer cells. Oncotarget 2017. 8 43008-43022. DOI:10.18632/oncotarget.17398.

  View
• March, 2017

  Aguilar A, et al. Discovery of 4‑((32R,42S,52R)‑63-Chloro-42-(3-chloro-2-fluorophenyl)12-ethyl-23-oxodispiro[cyclohexane-1,22-pyrrolidine-3′,33-indoline]52-carboxamido)bicyclo[2.2.2]octane-1-carboxylic Acid (AA-115/APG115): a potent and orally active murine double minute 2 (MDM2) inhibitor in clinical development. J Med Chem March 24, 2017. 60 2819-2839. DOI:10.1021/acs.jmedchem.6b01665.

  View
• October, 2016

  Li N, et al. A novel Smac mimetic APG-1387 demonstrates potent antitumor activity in nasopharyngeal carcinoma cells by inducing apoptosis. Cancer Lett 2016. 10 14-22. DOI:10.1016/j.canlet.2016.07.008.

  View
• November, 2014

  Lu J, Sheng R, Sun H, et al. A potent and highly efficacious bivalent Smac mimetic APG-1387 in phase I clinical development. 26th EORTC-NCI-AACR Symposium. . Poster 268

  View
• November, 2014

  Bai L, Chen L, Liu L, et al. BM-1252 (APG-1252): a potent dual specific Bcl-2/Bcl-xL inhibitor that achieves complete tumor regression with minimal platelet toxicity. Eur J Cancer 2014:50:109-10 November 01, 2014. Poster 338

  View
• November, 2014

  Wang H, et al. Preclinical studies of a dual BCL-2/BCL-XL inhibitor APG-1252 with strong anti-tumor efficacy and significantly reduced platelet toxicity. Abstract 544. Eur J Cancer 2014. 50(Suppl 6) 176-177. DOI:10.1016/S0959-8049(14)70670-7.

  View
• November, 2014

  Bai L, et al. BM-1252 (APG-1252): a potent dual specific BCL-2/BCL-XL inhibitor that achieves complete tumor regression with minimal platelet toxicity. Poster 338. Eur J Cancer 2014. 50 109-110. DOI:10.1016/S0959-8049(14)70464-2 .

  View
• January, 2013

  Ren X, et al. Identification of GZD824 as an orally bioavailable inhibitor that targets phosphorylated and nonphosphorylated breakpoint cluster region‒Abelson (BCR-ABL) kinase and overcomes clinically acquired mutation-induced resistance against imatinib. J Med Chem 2013. 56 879-894. DOI:10.1021/jm301581y.

  View
• Note: This is a select list of our scientific publications.